Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates

Abstract

Highlights

* CIGB-247 is a cancer therapeutic, based on recombinant modified VEGF as antigen, in combination with powerful adjuvant VSSP. * We extend the immunogenicity and safety studies of CIGB-247 in non human primates, scaling the antigen dose from 100μg to 200 and 400μg/vaccination. * Higher antigen doses had a positive influence in Ab titer maintenance and boosters achieve maximum Ab VEGF blocking activity, and specific T-cell responses. * Purified IgG from CIGB-247 immunized monkey produce biological effects in culture cells of endothelial origin. * Dose escalation was safe and well tolerated.